Submitted by Anonymous (not verified) on 6 August 2026 - 16:38
Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 7, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 7, Status: Authorised